Should gene therapy be used for AMD? new study asks patients

NCT ID NCT07004361

Recruiting now Knowledge-focused Sponsor: Nantes University Hospital Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study interviews 30 patients with wet age-related macular degeneration to understand their views on gene therapy. Researchers want to know if the benefits outweigh the risks of this irreversible treatment, and how patients make decisions about complex therapies. The goal is not to test a treatment, but to gather patient perspectives on ethical issues.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for EXUDATIVE AGE-RELATED MACULAR DEGENERATION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

macular degeneration wet macular degeneration

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

EXUDATIVE AGE-RELATED MACULAR DEGENERATION

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

CHU Nantes - Ophthalmology Department
RECRUITING

Nantes, Nantes, 44000, France

Contact Phone: •••-•••-•••• Email: •••••@•••••